Supreme Court asks why trade margin cap should not cover all medicines
October 12, 2026
AI summary — for doctors, generated from the source snippet
Why it matters
The government proposes a 30% trade-margin cap on patented and non-patented cancer medicines, but the Supreme Court asked why it cannot be extended to all medicines and medical products, and said DPCO-approved price-regulated medicines must reach patients.
Clinical relevance
A wider margin cap could change the prices of many essential medicines and devices that doctors prescribe.
This is an AI-generated summary of the source's own press release/snippet, not a clinical recommendation. Verify against the original source before acting on it.
Original source summary
Government proposes 30% trade-margin cap on patented and non-patented cancer medicines, but top court asks why a margin cap cannot be extended to all medicines and medical products; the court says the government has to ensure that DPCO-approved medicines, whose price is legally regulated, reach patients
Verbatim from The Hindu Health's own feed — "Supreme Court wants cap on trade margin for all essential medicines and medical products"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news